Cogent Biosciences
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
275 Wyman St Fl 3, Waltham, Massachusett...Phone Number
(617) 945-5576Website
www.cogentbio.comRevenue
-Stock Symbol
COGTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Explore more
Cogent Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cogent Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cogent Biosciences launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cogent Biosciences has new funding data
Click to see if Cogent Biosciences had a recent Job posting/layoffs
Check out if Cogent Biosciences is spiking on competitors!
Cogent Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Cogent Biosciences
Earning: See what the market has to say on Cogent Biosciences recently announced quarterly report
Check if Cogent Biosciences has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cogent Biosciences
Compare insights from companies similar to Cogent Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cogent Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cogent Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cogent Biosciences.
Cogent Biosciences financials insights
Gather financial insights about Cogent Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$12M
2015
Series B
$65M
2017
Debt
$15M
2018
Share Placement
$5M
Stock Offering
$69.2M
2020
Stock Offering
$25M
Share Placement
$104.4M
2025
Debt
$400M
Cogent Biosciences Tech Stack
A closer look at the technologies used by Cogent Biosciences
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Cogent Biosciences has announced plans to build a unified sales force of several dozen representatives to cover both its GIST and systemic mastocytosis indications, with key personnel already identified in preparation for commercial launch.
Hiring Plans
Project
Cogent Biosciences News & Media
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 12, Cogent Biosciences, Inc. (NASDAQ:COGT) presented early-stage preclinical data for its experimental drug CGT1145 at the European Hematology Association Congress in Stockholm, Sweden. The company presented the drug candidate as a potentially more precise and better-tolerated […]Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?
Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.’s share was trading at $34.81 as of June 1st. Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cogent Biosciences
Sign Up For FreeTo access detailed company insights
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives sys... Read More
